tDCS Shows Dual Impact on Depression and Comorbid Anxiety

Research has investigated the effects of transcranial direct current stimulation (tDCS) on individuals diagnosed with depression and comorbid anxiety. This noninvasive form of brain stimulation demonstrated a dual impact on participants, affecting both cognitive engagement and threat processing.

Key Findings from tDCS Study

Published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, the study revealed several outcomes:

Enhanced Task Engagement
tDCS led to improved accuracy, faster reaction times, and increased frontal brain activation during tasks.

This suggests a potential increase in executive function.

Heightened Threat Sensitivity
Contrary to hypotheses, tDCS did not reduce threat sensitivity. Instead, it unexpectedly increased amygdala activity—a brain region associated with threat processing—when tasks were less cognitively demanding. It also increased the eyeblink startle response under conditions of unpredictable threat.

Brain Region Activation
Frontal tDCS increased activation of the bilateral inferior frontal gyrus, a region linked to attention, specifically during cognitively demanding tasks.

Study Methodology

The study involved 101 individuals diagnosed with comorbid anxiety and depression. Participants were randomly divided into two distinct groups.

One group received a single 30-minute session of tDCS applied to the frontal cortex. The other group received sham (placebo) stimulation to ensure a controlled comparison.

Immediately following stimulation, all participants completed an attentional control task within an MRI scanner, which involved fearful face distractors. Subsequently, they performed an eyeblink startle task under the perceived threat of a mild electrical shock.

Clinical Implications and Future Directions

The findings suggest that tDCS could potentially serve as an adjunct treatment for major depressive disorder (MDD).

The findings suggest that tDCS could potentially serve as an adjunct treatment for major depressive disorder (MDD) when combined with therapies that benefit from increased attention and engagement.

However, a significant finding was that tDCS did not reduce threat sensitivity in this population, which is crucial for treatment planning. The clinical feasibility and scalability of tDCS, particularly through home-use devices and remotely supervised protocols, are noted as beneficial for expanding access to mental healthcare.

Despite recent FDA approval of home tDCS for depression, further research is required to fully understand how tDCS operates and for whom it is most effective.